PRESS RELEASE
17 SEPTEMBER 2024
British American Tobacco (BAT) launched a major global initiative to make a Smokeless World a reality during the company’s first ever Transformation Forum in London today.
The FTSE-listed company unveiled Omni™, an evidence-based, accessible and dynamic resource that shows how science and innovation can combine to achieve a Smokeless World. Omni™ can be accessed at https://www.asmokelessworld.com.
BAT’s Chief Corporate Officer, Kingsley Wheaton, said: “Tobacco Harm Reduction – encouraging smokers who would otherwise continue to smoke to switch completely to less risky alternatives – is the fastest route to achieving a Smokeless World. And we’re committed to working with others to make this a reality.
“While we have history of humans smoking tobacco for more than 8,000 years, innovation has now delivered smokeless products with reduced risks*† compared to cigarettes. We stand on the threshold of a breakthrough science-backed change.”
As a resource, Omni™ brings together hundreds of independent scientific studies, BAT’s own research into its innovations, and examples of Tobacco Harm Reduction in action, such as Sweden which stands on the cusp of becoming the first country to go smokeless as defined by the World Health Organization (WHO).
Omni™ also looks to answer some of the most challenging questions facing our industry and society, including:
BAT’s Director of Research and Science, and one of Omni™’s lead authors, Dr James Murphy, said: “With Omni™, BAT is showcasing its world-class research. Omni means all, and we are committed to opening it up to all stakeholders in the THR policy discussion so that we can seize this exciting opportunity to build a Smokeless World.
“We’re conscious that this will only be possible through genuine dialogue. That’s why we’re inviting anyone who shares our vision – including those who might disagree with us – to review the evidence and join the conversation.”
“Today’s event is only the beginning,” Murphy added. “Omni™ will be a dynamic resource – we are committed to continuing to publish our research going forward.
“We are building a technology-enabled Omni tool that will allow stakeholders in the THR policy discussion to further access our answers to the big questions facing our sector and society, rooted in evidence and science.”
“But Omni™ is more than a resource,” Wheaton said. “Our ambition is for Omni™ to be a platform for a necessary societal conversation founded in evidence, a manifesto for change and a mandate for action. All backed by the highest quality science and real-world evidence.
“A Smokeless World will only be achieved through the adoption of tobacco harm reduction, and this will require more dialogue and whole-of-society solutions. We’re ready to lead and be part of that dialogue. It’s too important not to”.
* Based on the weight of evidence and assuming a complete switch from cigarettes smoking. These products are not risk free and are addictive.
† Our Vapour product Vuse (including Alto, Solo, Ciro and Vibe), and certain products, including Velo, Grizzly, Kodiak, and Camel Snus, which are sold in the U.S., are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
Media Centre
+44 (0) 20 7845 2888 (24 hours) | info@asmokelessworld.com | @smokelessworld
Investor Relations
Victoria Buxton: +44 (0)20 7845 2012 | IR_team@bat.com
This release contains certain forward-looking statements, including "forward-looking" statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "expect," "estimate," "project," "positioned," "strategy," "outlook", "target" and similar expressions. These include statements regarding our customer target ambition, New Categories revenue targets and our ESG targets.
All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this release are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. A review of the reasons why actual results and developments may differ materially from the expectations disclosed or implied within forward-looking statements can be found by referring to the information contained under the headings “Cautionary Statement” and "Group Principal Risks " in the 2023 Annual Report and Form 20-F of British American Tobacco p.l.c. (BAT).
Additional information concerning these and other factors can be found in BAT's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, http://www.sec.gov and BAT’s Annual Reports, which may be obtained free of charge from the BAT website www.bat.com.
Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and information available at the date of preparation of this release and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.